A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe

According to a recent press release from Bluebird Bio, the European Medicines Agency has accepted and will review their marketing authorization application (MAA) for the investigational gene therapy LentiGlobin™ as…

Continue Reading
Close Menu